Qiagen (NYSE:QGEN - Get Free Report) is set to announce its earnings results after the market closes on Wednesday, November 6th. Analysts expect the company to announce earnings of $0.54 per share for the quarter. Parties that are interested in participating in the company's conference call can do so using this link.
Qiagen (NYSE:QGEN - Get Free Report) last posted its earnings results on Wednesday, July 31st. The company reported $0.55 earnings per share for the quarter, beating the consensus estimate of $0.52 by $0.03. The business had revenue of $496.00 million during the quarter, compared to the consensus estimate of $495.45 million. Qiagen had a return on equity of 12.92% and a net margin of 3.75%. The business's quarterly revenue was down .2% on a year-over-year basis. During the same period in the previous year, the business earned $0.53 EPS. On average, analysts expect Qiagen to post $2 EPS for the current fiscal year and $2 EPS for the next fiscal year.
Qiagen Stock Performance
NYSE:QGEN traded up $0.41 during mid-day trading on Wednesday, reaching $42.24. 928,685 shares of the stock were exchanged, compared to its average volume of 1,172,055. The stock has a market capitalization of $9.64 billion, a P/E ratio of 28.35, a P/E/G ratio of 3.17 and a beta of 0.39. Qiagen has a 1 year low of $36.10 and a 1 year high of $47.44. The company has a 50 day simple moving average of $44.48 and a 200-day simple moving average of $43.57. The company has a quick ratio of 1.46, a current ratio of 1.77 and a debt-to-equity ratio of 0.27.
Wall Street Analyst Weigh In
Several research firms recently commented on QGEN. HSBC downgraded shares of Qiagen from a "buy" rating to a "hold" rating and set a $49.00 price target for the company. in a research report on Thursday, October 17th. Robert W. Baird increased their target price on shares of Qiagen from $49.00 to $52.00 and gave the stock an "outperform" rating in a research note on Friday, August 2nd. Finally, Hsbc Global Res raised Qiagen to a "hold" rating in a report on Thursday, October 17th. Five research analysts have rated the stock with a hold rating and six have given a buy rating to the company's stock. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus price target of $50.12.
View Our Latest Stock Report on QGEN
About Qiagen
(
Get Free Report)
QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide. The company provides primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories.
Featured Articles
Before you consider Qiagen, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Qiagen wasn't on the list.
While Qiagen currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
